InflaRx

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

carnival cruise shutter

News

Price Target

Pre-Market Outlook

Markets

Analyst Ratings

Trading Ideas

HUBG

HURN

IFRX

KRUS

Carnival To Rally Over 50%? Here Are 10 Top Analyst Forecasts For Wednesday

Penny Stocks

Small Cap

Movers

APTO

AREB

CISS

CVKD

Intelligent Bio Solutions Inc. - Common Stock

INBS

INTC

JAGX

KLAC

ONCO

REVB

TCBP

TELL

VMAR

WLGS

YIBO

Shares of  Tellurian Inc. (NASDAQ: TELL) shares rose sharply in pre-market trading following a report suggesting the company hired Lazard to explore a possible sale.

Tellurian shares jumped 16.3% to $0.6050 in pre-market trading

Why Tellurian Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket

AAPL

ARBB

BDRX

BILL

CYTO

DMTK

DOCN

EIGR

EZGO

FOXF

FTNT

HIPO

INSG

INVO

MCAF

NVOS

RVSN

SECO

Gainers

Altamira Therapeutics Ltd (NASDAQ: CYTO) shares surged 54.1% to $0.25 in pre-market trading after gaining 5% on Thursday.

Why DigitalOcean Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

InflaRx NV

Press Releases

General

InflaRx Receives European Commission Approval for GOHIBIC® (vilobelimab) for the Treatment of SARS-CoV-2-Induced Acute Respiratory Distress Syndrome (ARDS)

InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference

Financing

InflaRx Announces Public Offering of Ordinary Shares and Pre-Funded Warrants

InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Infinitum: Pioneering Quantum-Proof Blockchain Solutions to Transform Finance

InflaRx Announces Closing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

InflaRx to Report Full Year 2024 Results on March 20 and Announces Participation in March Investor Conferences

Health Care

InflaRx to Showcase Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

InflaRx Showcases Vilobelimab's Role in Immuno-Dermatology at the 2025 AAD Annual Meeting

Earnings

InflaRx Reports Full Year 2024 Results and Highlights Key Achievements and Expected Milestones

Comments

InflaRx

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga